focus -WSS

focus

author：leisure time 2025-09-28 20:17:58 Page View：381

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Doctors in states that ban abortion can still help patients
Next article： Psychedelics group wrestles with new pharma identity

comprehensive

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

A Greenpeace activist is fined for crash

FILE-TheGermanplayerslookonasaGreenpeaceparagliderlandsinthestadiumpriortotheEuro2020soccerchampions

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

FILE-U.SsoccerplayerMeganRapinoespeakstoreportersduringthe2023Women'sWorldCupmediadayfortheUnitedSta

focus

explore

comprehensive

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup